arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2017-23-6-517-528arthyper-714Research ArticleОРИГИНАЛЬНАЯ СТАТЬЯORIGINAL ARTICLEРЕНАЛЬНО-АССОЦИИРОВАННЫЙ ЭФФЕКТ «УСКОЛЬЗАНИЯ» АНТИГИПЕРТЕНЗИВНОЙ ТЕРАПИИ У ПАЦИЕНТОВ С АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИЕЙ НА ФОНЕ ПРИЕМА НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (РЕЗУЛЬТАТЫ КОГОРТНОГО ИССЛЕДОВАНИЯ «ПАНДА»)RENAL-ASSOCIATED ESCAPE EFFECT OF ANTIHYPERTENSIVE THERAPY IN HYPERTENSIVE PATIENTS RECEIVING NONSTEROIDAL ANTI-INFLAMMA‑ TORY DRUGS (“PANDA” TRIAL)ЗолотовскаяИ. А.ZolotovskayaI. A.

Золотовская Ирина Александровна — кандидат медицинских наук, ассистент кафедры госпитальной терапии с курсом поликлинической терапии и трансфузиологии. 

Самара.

Irina A. Zolotovskaya, MD, PhD, Assistent, Department of Hospital Therapy with the Courses of Outpatient Therapy and Transfusion. 

Samara.

zolotovskay@list.ruДавыдкинИ. Л.DavydkinI. L.

Давыдкин Игорь Леонидович — доктор медицинских наук, профессор, проректор по научной и инновационной работе, заведующий кафедрой госпитальной терапии с курсом поликлинический терапии и трансфузиологии, директор научноисследовательского института гематологии, трансфузиологии и интенсивной терапии, главный внештатный гематолог Министерства здравоохранения Самарской области.

 

Igor L. Davydkin, MD, PhD, DSc, Professor, Head, Department of Hospital Therapy with the Courses of Outpatient Therapy and Transfusion, Director Institute of Hematology, Transfusion and Intensive Therapy.

Samara.

БоровковаН. Ю.BorovkovaN. Yu.

Боровкова Наталья Юрьевна — доктор медицинских наук, профессор кафедры госпитальной терапии. 

Нижний Новгород.

Natal’ya Yu. Borovkova, MD, PhD, DSc, Professor, Head, Department of Hospital Therapy.

Федеральное государственное образовательное учреждение  высшего образования «Самарский государственный  медицинский университет» Министерства здравоохранения  Российской Федерации.РоссияSamara State Medical University.Russian FederationФедеральное государственное образовательное учреждение  высшего образования «Нижегородская медицинская  государственная академия» Министерства здравоохранения  Российской Федерации. РоссияNizhny Novgorod State Medical Academy.Russian Federation201711012018236517528Copyright © Золотовская И.А., Давыдкин И.Л., Боровкова Н.Ю., 20182018Золотовская И.А., Давыдкин И.Л., Боровкова Н.Ю.Zolotovskaya I.A., Davydkin I.L., Borovkova N.Y.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/714нестероидные противовоспалительные препаратыскорость клубочковой фильтрациицистатин Сартериальная гипертензияартериальное давлениеснижение эффективности антигипертензивных препаратовnonsteroidal anti-inflammatory drugsglomerular filtration ratecystatin Carterial hypertensionblood pressuredecreased effectiveness of antihypertensive drugsReferencesCroff L. Prostanoid biology and its therapeutic targeting. In Kelley’s Textbook of Rheumatology. Ed. by Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’Dell JR. 9th edition. Philadelphia: Saunders. 2013:871–893.Croff L. Prostanoid biology and its therapeutic targeting. In Kelley’s Textbook of Rheumatology. Ed. by Firestein GS, Budd RC, Gabriel SE, McInnes IB, O’Dell JR. 9th edition. Philadelphia: Saunders. 2013:871–893.Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56(3):387. doi:10.1124/pr.56.3.3Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev. 2004;56(3):387. doi:10.1124/pr.56.3.3Llorens O, Perez JJ, Palomar A, Mauleon D. Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002;20(5):359–371.Llorens O, Perez JJ, Palomar A, Mauleon D. Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002;20(5):359–371.Allison SJ. Hypertension: Haematopoietic COX-2 in salt-sensitive hypertension. Nat Rev Nephrol. 2016;12(1):3. doi:10.1038/nrneph.2015.182Allison SJ. Hypertension: Haematopoietic COX-2 in salt-sensitive hypertension. Nat Rev Nephrol. 2016;12(1):3. doi:10.1038/nrneph.2015.182Winkelmayer WC, Waikar SS, Mogun H, Solomon DH. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med. 2008;121(12):1092–1098. doi:10.1016/j.amjmed.2008.06.035Winkelmayer WC, Waikar SS, Mogun H, Solomon DH. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am J Med. 2008;121(12):1092–1098. doi:10.1016/j.amjmed.2008.06.035Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38. doi:10.1038/ajg.2009.115Lanza FL, Chan FK, Quigley EM. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38. doi:10.1038/ajg.2009.115Lanas A, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L, Calvet X et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulant. Clin Gastroenterol Hepatol. 2015;13(5):906–912. doi:10.1016/j.cgh.2014.11.007Lanas A, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L, Calvet X et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulant. Clin Gastroenterol Hepatol. 2015;13(5):906–912. doi:10.1016/j.cgh.2014.11.007Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal antiinflammatory drugs and risk of acute kidney injury: nested case-control study. Br Med J. 2013;346: e8525. doi:10.1136/bmj.e8525Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal antiinflammatory drugs and risk of acute kidney injury: nested case-control study. Br Med J. 2013;346: e8525. doi:10.1136/bmj.e8525Taubert КА. Cardiology patient pages: can patients with cardiovascular disease take nonsteroidal antiinflammatory drugs? Circulation. 2008;117(17):322–324. doi:10.1161/ CIRCULATIONAHA.107.749135Taubert КА. Cardiology patient pages: can patients with cardiovascular disease take nonsteroidal antiinflammatory drugs? Circulation. 2008;117(17):322–324. doi:10.1161/ CIRCULATIONAHA.107.749135Li H, Hortmann M, Daiber A, Oelze M, Ostad MA, Schwarz PM et al. Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J Pharmacol Exp Ther. 2008;326(3):745–53. doi:10.1124/jpet.108.139030Li H, Hortmann M, Daiber A, Oelze M, Ostad MA, Schwarz PM et al. Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases. J Pharmacol Exp Ther. 2008;326(3):745–53. doi:10.1124/jpet.108.139030Vázquez-Meza H, de Piña MZ, Pardo JP, Riveros-Rosas H, Villalobos-Molina R, Piña E. Non-steroidal antiinflammatory drugs activate NADPH oxidase in adipocytes and raise the H2O2 pool to prevent cAMP-stimulated protein kinase a activation and inhibit lipolysisю. BMC Biochem. 2013;30(14):13. doi:10.1186/1471– 2091–14–13Vázquez-Meza H, de Piña MZ, Pardo JP, Riveros-Rosas H, Villalobos-Molina R, Piña E. Non-steroidal antiinflammatory drugs activate NADPH oxidase in adipocytes and raise the H2O2 pool to prevent cAMP-stimulated protein kinase a activation and inhibit lipolysisю. BMC Biochem. 2013;30(14):13. doi:10.1186/1471– 2091–14–13US Food and Drug Administration. Thrombotic cardiovascular events associated with NSAID use: regulatory history and results of literature search (RCTs), in proceedings of the joint meeting of the arthritis advisory committee and drug safety and risk management advisory committee. 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMate-rials/Drugs/ArthritisAdvisoryCommittee/UCM383180.pdfUS Food and Drug Administration. Thrombotic cardiovascular events associated with NSAID use: regulatory history and results of literature search (RCTs), in proceedings of the joint meeting of the arthritis advisory committee and drug safety and risk management advisory committee. 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMate-rials/Drugs/ArthritisAdvisoryCommittee/UCM383180.pdfFosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190–7. doi:10.1038/clpt.2008.204Fosbøl EL, Gislason GH, Jacobsen S, Folke F, Hansen ML, Schramm TK et al. Risk of myocardial infarction and death associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) among healthy individuals: a nationwide cohort study. Clin Pharmacol Ther. 2009;85(2):190–7. doi:10.1038/clpt.2008.204Bacic-Vrca V, Marusic S, Erdeljic V, Falamic S, Gojo-Tomic N, Rahelic D. The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci. 2010;32(6):815–21. doi:10.1007/s11096–010–9442–5Bacic-Vrca V, Marusic S, Erdeljic V, Falamic S, Gojo-Tomic N, Rahelic D. The incidence of potential drug-drug interactions in elderly patients with arterial hypertension. Pharm World Sci. 2010;32(6):815–21. doi:10.1007/s11096–010–9442–5Andrassy KM. Comments on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;84(3):622–3. doi:10.1038/ki.2013.243Andrassy KM. Comments on KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;84(3):622–3. doi:10.1038/ki.2013.243Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Российский кардиологический журнал. 2014;1(105):7–94. [The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Russian Journal of Cardiology. 2014;1(105):7–94. In Russian].Рекомендации по лечению артериальной гипертонии. ESH/ESC 2013. Российский кардиологический журнал. 2014;1(105):7–94. [The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Russian Journal of Cardiology. 2014;1(105):7–94. In Russian].Campbell WB, Gomez-Sanchez CE, Adams BV, Schmitz JM, Itskovitz HD. Attenuation of angiotensin II and III-induced aldosterone release by prostaglandin synthesis inhibitors. J Clin Invest. 1979;64(6):1552–1557. doi:10.1172/JCI109615Campbell WB, Gomez-Sanchez CE, Adams BV, Schmitz JM, Itskovitz HD. Attenuation of angiotensin II and III-induced aldosterone release by prostaglandin synthesis inhibitors. J Clin Invest. 1979;64(6):1552–1557. doi:10.1172/JCI109615Kramer HJ, Glänzer K, Düsing R. Role of prostaglandins in the regulation of renal water excretion. Kidney Int. 1981;19 (6):851–859.Kramer HJ, Glänzer K, Düsing R. Role of prostaglandins in the regulation of renal water excretion. Kidney Int. 1981;19 (6):851–859.Walker RM, Brown RS, Stoff JS. Role of renal prostaglandins during antidiuresis and water diuresis in man. Kidney Int. 1982;21 (2):365–370.Walker RM, Brown RS, Stoff JS. Role of renal prostaglandins during antidiuresis and water diuresis in man. Kidney Int. 1982;21 (2):365–370.Nasjletti A. Arthur C. Corcoran Memorial Lecture. The role of eicosanoids in angiotensin-dependent hypertension. Hypertension. 1998;31(1 Pt 2):194–200.Nasjletti A. Arthur C. Corcoran Memorial Lecture. The role of eicosanoids in angiotensin-dependent hypertension. Hypertension. 1998;31(1 Pt 2):194–200.Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used nonnarcotic analgesics on blood pressure level in adults. J Hypertens. 2006;24 (8):1457–1469. doi:10.1097/01.hjh.0000239278.82196.a5Wilson SL, Poulter NR. The effect of non-steroidal anti-inflammatory drugs and other commonly used nonnarcotic analgesics on blood pressure level in adults. J Hypertens. 2006;24 (8):1457–1469. doi:10.1097/01.hjh.0000239278.82196.a5Schlondorff D. Renal complications of nonsteroidal antiinflammatory drugs. Kidney Int. 1993;44(3):643–653.Schlondorff D. Renal complications of nonsteroidal antiinflammatory drugs. Kidney Int. 1993;44(3):643–653.Zadražil J. Nonsteroidal antiinflammatory drugs and the kidney. Vnitř Lék. 2006;52(7–8):686–90.Zadražil J. Nonsteroidal antiinflammatory drugs and the kidney. Vnitř Lék. 2006;52(7–8):686–90.Gavrilescu CM, Felea MG, Barbu R, Duma O, Bodescu MM, Midilina Bodescul M et al. Assessment of adverse drug reactions as cardiovascular risk factors. Rev Med Chir Soc Med Nat Iasi. 2016;120(1):48–54.Gavrilescu CM, Felea MG, Barbu R, Duma O, Bodescu MM, Midilina Bodescul M et al. Assessment of adverse drug reactions as cardiovascular risk factors. Rev Med Chir Soc Med Nat Iasi. 2016;120(1):48–54.Pavlicević I, Kuzmanić M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008;15(3):372–82.Pavlicević I, Kuzmanić M, Rumboldt M, Rumboldt Z. Interaction between antihypertensives and NSAIDs in primary care: a controlled trial. Can J Clin Pharmacol. 2008;15(3):372–82.Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther. 2007;29(Suppl):2477–97. doi:10.1016/j. clinthera.2007.12.003Hersh EV, Pinto A, Moore PA. Adverse drug interactions involving common prescription and over-the-counter analgesic agents. Clin Ther. 2007;29(Suppl):2477–97. doi:10.1016/j. clinthera.2007.12.003Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005;11(14):1795–1804. doi:10.2174/1381612053764922Cheng HF, Harris RC. Renal effects of non-steroidal anti-inflammatory drugs and selective cyclooxygenase-2 inhibitors. Curr Pharm Des. 2005;11(14):1795–1804. doi:10.2174/1381612053764922Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int. 2006;70(8):1495–1502. doi:10.1038/sj.ki.5001766Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kidney Int. 2006;70(8):1495–1502. doi:10.1038/sj.ki.5001766Hernanz R, Briones AM, Salaices M, Alonso MJ. New roles for old pathways? A circuitous relationship between reactive oxygen species and cyclo-oxygenase in hypertension. Clin Sci (Lond). 2014;126(2):111–121. doi:10.1042/CS20120651Hernanz R, Briones AM, Salaices M, Alonso MJ. New roles for old pathways? A circuitous relationship between reactive oxygen species and cyclo-oxygenase in hypertension. Clin Sci (Lond). 2014;126(2):111–121. doi:10.1042/CS20120651Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012;4(132):132–54. doi:10.1126/ scitranslmed.3003787Yu Y, Ricciotti E, Scalia R, Tang SY, Grant G, Yu Z et al. Vascular COX-2 modulates blood pressure and thrombosis in mice. Sci Transl Med. 2012;4(132):132–54. doi:10.1126/ scitranslmed.3003787Facemire CS, Griffiths R, Audoly LP, Koller BH, Coffman TM. The impact of microsomal prostaglandin E synthase 1 on blood pressure is determined by genetic background. Hypertension. 2010;55 (2):531–538. doi:10.1161/HYPERTENSIONAHA.109.145631Facemire CS, Griffiths R, Audoly LP, Koller BH, Coffman TM. The impact of microsomal prostaglandin E synthase 1 on blood pressure is determined by genetic background. Hypertension. 2010;55 (2):531–538. doi:10.1161/HYPERTENSIONAHA.109.145631

The authors declare that there are no conflicts of interest present.